The IGF2BP3 Knockout PaTu 8988t Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population in which the gene encoding the RNA-binding protein IGF2BP3 has been disrupted in the human PaTu 8988t pancreatic ductal adenocarcinoma cell line. This loss-of-function model is designed for detailed investigation of IGF2BP3-dependent post-transcriptional regulatory networks and their contributions to cancer progression and metastasis.
The parental PaTu 8988t cell line is derived from a liver metastasis of a human pancreatic ductal adenocarcinoma and is characterized by an activating KRAS mutation alongside wild-type TP53. This genetic makeup mirrors the molecular profile of metastatic pancreatic cancer, making it an established and clinically relevant model for studying tumor cell invasion, dissemination, and therapeutic resistance. The cells retain the invasive properties typical of advanced pancreatic adenocarcinomas and provide a platform to examine IGF2BP3 function in a setting of constitutive KRAS signaling.
IGF2BP3 is an m6A-binding protein that recognizes methylated adenosines on target mRNAs, thereby enhancing their stability and translation. It is a direct transcriptional target of MYC and is also activated downstream of KRAS and EGFR signaling. Key downstream targets include the mRNAs for MYC, CD44, CTNNB1, IGF2, and HMGA2, which encode drivers of cell cycle progression, invasion, and metastasis. IGF2BP3 physically interacts with the paralogous proteins IGF2BP1 and IGF2BP2, the translation initiation factor EIF4E, the m6A eraser YTHDF2, and the RNA-binding protein HuR (ELAVL1). Through these interactions, it integrates signals from the PI3K/AKT/mTOR pathway, the Wnt/??-catenin cascade, and the MYC transcriptional program, forming a multipronged hub that amplifies oncogenic signaling. This network sustains expression of ??-catenin (CTNNB1) and the stemness marker CD44, thereby promoting epithelial-mesenchymal transition and metastatic competence.
In the PaTu 8988t knockout model, disruption of IGF2BP3 permits direct assessment of how loss of this RNA-binding protein alters the stability and translation of critical oncogenic transcripts in a KRAS-mutated background. The polyclonal nature of the population maintains genetic heterogeneity, avoiding artifacts associated with clonal selection, and enables the study of population-level responses to IGF2BP3 loss. This model is particularly suited for evaluating the dependency of metastatic signaling on IGF2BP3 and for probing potential feedback or compensatory mechanisms involving other m6A readers or RNA-binding proteins.
Researchers can employ these cells in a wide range of biochemical and functional assays. Protein-level changes can be monitored by western blotting for IGF2BP3 and its targets, while RT-qPCR and RNA immunoprecipitation (RIP) can be used to quantify mRNA stability and direct protein?CRNA interactions. Functional consequences on proliferation, migration, and invasion are assessed using standard Transwell and growth curve assays. Transcriptome-wide approaches such as RNA-seq and m6A-RIP-seq can map the global impact on gene expression and the m6A epitranscriptome, and co-immunoprecipitation experiments can delineate altered protein interaction networks. Applications include fundamental studies of RNA-binding proteins in cancer, epitranscriptomic regulation, drug target validation, and elucidation of resistance mechanisms in pancreatic adenocarcinoma. For further information, please contact Ascent Research.
